CA2609549A1 - Treatment of eye disorders with sirtuin modulators - Google Patents

Treatment of eye disorders with sirtuin modulators Download PDF

Info

Publication number
CA2609549A1
CA2609549A1 CA002609549A CA2609549A CA2609549A1 CA 2609549 A1 CA2609549 A1 CA 2609549A1 CA 002609549 A CA002609549 A CA 002609549A CA 2609549 A CA2609549 A CA 2609549A CA 2609549 A1 CA2609549 A1 CA 2609549A1
Authority
CA
Canada
Prior art keywords
compound
formula
attendant definitions
sirtuin
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609549A
Other languages
English (en)
French (fr)
Inventor
Michael Milburn
Christoph H. Westphal
David J. Livingston
Philip Lambert
Karl D. Normington
Peter Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2609549A1 publication Critical patent/CA2609549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002609549A 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators Abandoned CA2609549A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US60/684,252 2005-05-25
US73155005P 2005-10-28 2005-10-28
US60/731,550 2005-10-28
US78835806P 2006-03-30 2006-03-30
US60/788,358 2006-03-30
PCT/US2006/020406 WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Publications (1)

Publication Number Publication Date
CA2609549A1 true CA2609549A1 (en) 2006-11-30

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609549A Abandoned CA2609549A1 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Country Status (5)

Country Link
EP (1) EP1928440A2 (https=)
JP (1) JP2008542296A (https=)
AU (1) AU2006249816A1 (https=)
CA (1) CA2609549A1 (https=)
WO (1) WO2006127987A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
KR101657326B1 (ko) 2009-02-04 2016-09-19 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤 조성물
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
JP5955750B2 (ja) * 2012-11-20 2016-07-20 株式会社東洋新薬 皮膚外用剤
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2017004101A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004100A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
EP3236928B1 (en) 2016-01-11 2020-12-09 The Procter and Gamble Company Method of treating a skin condition and compositions therefor
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
WO2018030389A1 (ja) * 2016-08-08 2018-02-15 学校法人 慶應義塾 Ｎａｄ関連代謝産物の利用
US10898738B2 (en) 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
JP6871400B2 (ja) * 2016-11-14 2021-05-12 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法
SG11201908251YA (en) * 2017-03-07 2019-10-30 Cempra Pharmaceuticals Inc Compositions and methods for treating dry eye diseases
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
US20220370484A1 (en) * 2019-06-25 2022-11-24 Senju Pharmaceutical Co., Ltd. Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr)
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE68910113T2 (de) * 1988-01-19 1994-03-17 Childrens Hospital Corp Wachstuminhibierendes mittel und dessen verwendung.
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
EP1140050B1 (en) * 1998-12-24 2003-12-03 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (ja) * 1999-03-31 2000-12-12 Sunstar Inc スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ES2190771B2 (es) * 2002-01-24 2004-03-01 Univ Alicante Procedimiento para la produccion de resveratrol en cultivos celulares.
JP2003252760A (ja) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp 網膜疾患治療剤および／または予防剤
CN1220486C (zh) * 2002-11-15 2005-09-28 董英杰 白藜芦醇类化合物的β－环糊精或其衍生物的包合物及其制备方法
EP2301549A1 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2529510A1 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
CN1925862A (zh) * 2003-10-10 2007-03-07 雷斯弗洛吉克斯公司 与egr－1增强子元件有关的疾病的治疗
DE102004002787A1 (de) * 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Also Published As

Publication number Publication date
JP2008542296A (ja) 2008-11-27
EP1928440A2 (en) 2008-06-11
WO2006127987A2 (en) 2006-11-30
AU2006249816A1 (en) 2006-11-30
WO2006127987A3 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
AU2006230478B2 (en) Treatment of eye disorders with sirtuin modulators
CA2609549A1 (en) Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
CN107708664B (zh) 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
EP2600850B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
US9925149B2 (en) Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
CA2537820C (en) Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
TW201836605A (zh) 1,2,4-二唑苯甲酸之鹽及醫藥組合物
JP2020073564A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
KR20170097601A (ko) 생물활성, 나노입자포집된 항산화제의 운반
Shree et al. Applications of nanotechnology-mediated herbal nanosystems for ophthalmic drug
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
US10583101B2 (en) Lipid formulations of carmustine
KR101771483B1 (ko) 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물
Cetin A review on ophthalmic delivery systems containing flavonoids for the treatment of eye diseases
JP6502393B2 (ja) ニコチンと酸化セリウムとのナノ粒子複合体及びその使用
Khin Development of fenofibrate/cyclodextrin complex loaded eudragit nanoparticles for ocular delivery
KUMAR et al. NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS
JP2026501608A (ja) 眼の状態の治療のためのナビロンを含む医薬組成物
Ghosal et al. Pelagia Research Library
HK1098450B (en) Process for preparing water soluble diterpenes and their applications

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140328